KALA BIO Directors Plan Conditional Resignations Tied to Vote

KALA BIO ( (KALA) ) has shared an update.

On December 19, 2025, six directors of KALA BIO—Marjan Farid, M.D., Andrew I. Koven, C. Daniel Myers, Todd Bazmore, Mark Iwicki, and Howard B. Rosen—submitted conditional resignations that would become effective immediately after the company’s 2025 annual meeting if shareholders approve both the issuance of common stock upon conversion of certain preferred shares and an increase in authorized common stock. The move, which the company stated was not due to any disagreement over operations, policies or practices, would significantly reshape KALA BIO’s board composition after the 2025 annual meeting, while David Lazar is expected to remain on the board as a Class II director regardless of the vote outcome, highlighting governance changes tied directly to forthcoming capital-structure decisions.

The most recent analyst rating on (KALA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on KALA BIO stock, see the KALA Stock Forecast page.

Spark’s Take on KALA Stock

According to Spark, TipRanks’ AI Analyst, KALA is a Underperform.

Kala Pharmaceuticals faces significant financial difficulties, marked by declining revenues and heavy reliance on debt, which pose serious risks. The technical analysis reflects a strong downtrend, with the stock being oversold, adding to the negative outlook. Valuation is unattractive due to negative earnings and the lack of a dividend, further weighing down the stock’s appeal.

To see Spark’s full report on KALA stock, click here.

More about KALA BIO

Average Trading Volume: 7,663,331

Technical Sentiment Signal: Sell

Current Market Cap: $14.25M

For detailed information about KALA stock, go to TipRanks’ Stock Analysis page.